| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:09:36 -0700 |
| HMDB ID |
HMDB00929 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
L-Tryptophan |
| Description |
Tryptophan is an essential amino acid which is the precursor of serotonin. Serotonin is a brain neurotransmitter, platelet clotting factor and neurohormone found in organs throughout the body. Metabolism of tryptophan to serotonin requires nutrients such as vitamin B6, niacin and glutathione. Niacin is an important metabolite of tryptophan. High corn or other tryptophan-deficient diets can cause pellagra, which is a niacin-tryptophan deficiency disease with symptoms of dermatitis, diarrhea and dementia. Inborn errors of tryptophan metabolism exist where a tumor (carcinoid) makes excess serotonin. Hartnup's disease is a disease where tryptophan and other amino acids are not absorbed properly. Tryptophan supplements may be useful in each condition, in carcinoid replacing the over-metabolized nutrient and in Hartnup's supplementing a malabsorbed nutrient. Some disorders of excess tryptophan in the blood may contribute to mental retardation. Assessment of tryptophan deficiency is done through studying excretion of tryptophan metabolites in the urine or blood. Blood may be the most sensitive test because the amino acid tryptophan is transported in a unique way. Increased urination of tryptophan fragments correlates with increased tryptophan degradation, which occurs with oral contraception, depression, mental retardation, hypertension and anxiety states. The requirement for tryptophan and protein decreases with age. Adults' minimum daily requirement is 3 mg/kg/day or about 200 mg a day. This may be an underestimation, for there are 400 mg of tryptophan in just a cup of wheat germ. A cup of low fat cottage cheese contains 300 mg of tryptophan and chicken and turkey contain up to 600 mg per pound. (http://www.dcnutrition.com). |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (-)-tryptophan
- (2S)-2-amino-3-(1H-indol-3-yl)propanoate
- (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
- (L)-tryptophan
- (S)-1H-Indole-3-alanine
- (S)-2-Amino-3-(3-indolyl)propionic acid
- (S)-a-Amino-1H-indole-3-propanoate
- (S)-a-Amino-1H-indole-3-propanoic acid
- (S)-a-amino-b-indolepropionate
- (S)-a-amino-b-indolepropionic acid
- (S)-a-Aminoindole-3-propionate
- (S)-a-Aminoindole-3-propionic acid
- (S)-alpha-Amino-1H-indole-3-propanoate
- (S)-alpha-Amino-1H-indole-3-propanoic acid
- (S)-alpha-Amino-beta-(3-indolyl)-propionic acid
- (S)-alpha-amino-beta-indolepropionate
- (S)-alpha-amino-beta-indolepropionic acid
- (S)-alpha-Aminoindole-3-propionate
- (S)-alpha-Aminoindole-3-propionic acid
- (S)-tryptophan
- 1-beta-3-Indolylalanine
- 1beta-3-Indolylalanine
- 1H-Indole-3-Alanine
- 2-Amino-3-indolylpropanoate
- 2-Amino-3-indolylpropanoic acid
- 3-(1H-Indol-3-yl)-L-Alanine
- 3-Indol-3-ylalanine
- alpha'-Amino-3-indolepropionic acid
- alpha-Aminoindole-3-propionic acid
- Ardeytropin
- H-TRP-oh
- Indole-3-alanine
- Kalma
- L-(-)-Tryptophan
- L-alpha-Amino-3-indolepropionic acid
- L-alpha-Aminoindole-3-propionic acid
- L-b-3-Indolylalanine
- L-beta-3-Indolylalanine
- L-Tryptofan
- L-Tryptophan
- L-Tryptophane
- Lopac-T-0254
- Lyphan
- Optimax
- Pacitron
- Sedanoct
- Triptofano
- Trofan
- Tryptacin
- Tryptan
- Tryptophan
- Tryptophane
- Tryptophanum
|
| Chemical Formula |
C11H12N2O2 |
| Average Molecular Weight |
204.2252 |
| Monoisotopic Molecular Weight |
204.089877638 |
| IUPAC Name |
(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid |
| Traditional IUPAC Name |
L-tryptophan |
| CAS Registry Number |
73-22-3 |
| SMILES |
N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O |
| InChI Identifier |
InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1 |
| InChI Key |
QIVBCDIJIAJPQS-VIFPVBQESA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Amino Acids, Peptides, and Analogues |
| Class |
Amino Acids and Derivatives |
| Sub Class |
Alpha Amino Acids and Derivatives |
| Other Descriptors |
- Aromatic Heteropolycyclic Compounds
- Common amino acids(KEGG)
- amino acid zwitterion(ChEBI)
|
| Substituents |
- Carboxylic Acid
- Indole
- Indolyl Carboxylic Acid Derivative
- Primary Aliphatic Amine (Alkylamine)
- Pyrrole
- Tryptamine
|
| Direct Parent |
Alpha Amino Acids and Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Component of Aminoacyl-tRNA biosynthesis
- Component of Histidine metabolism
- Component of Indole and ipecac alkaloid biosynthesis
- Component of Phenylalanine metabolism
- Component of Tryptophan metabolism
- Component of Tyrosine metabolism
- Essential amino acid
|
| Application |
Not Available |
| Cellular locations |
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
230 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
13.4 mg/mL at 25 °C |
YALKOWSKY,SH & DANNENFELSER,RM (1992) |
| LogP |
-1.06 |
HANSCH,C ET AL. (1995) |
|
| Predicted Properties |
|
| Spectra |
|
| Gas-MS Spectrum |
| 13C NMR Spectrum |
| 1H NMR Spectrum |
| MS/MS Spectrum Quattro_QQQ 10 |
| MS/MS Spectrum Quattro_QQQ 25 |
| MS/MS Spectrum Quattro_QQQ 40 |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| [1H,1H] 2D NMR Spectrum |
| [1H,13C] 2D NMR Spectrum |
|
| Biological Properties |
| Cellular Locations |
|
| Biofluid Locations |
- Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
| Tissue Location |
- Fibroblasts
- Prostate
- Nerve Cells
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
54.5 +/- 9.7 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
78.4 +/- 15.5 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
44.0 (37.0-51.0) uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
48.7 +/- 11.6 uM |
Adult (>18 years old) |
Female |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
101.5 +/- 27.2 uM |
Newborn (0-30 days old) |
Both |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
45.0 +/- 9.0 uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
5 +/- 3 uM |
Not Specified |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.3 +/- 0.4 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.32 +/- 0.09 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.25 +/- 0.95 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
20.4 +/- 8.2 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.0 +/- 0.53 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.0 (1.2-2.5) uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
15.9 +/- 4.1 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.64 +/- 0.52 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Saliva |
Detected and Quantified |
|
0.5 +/- 0.5 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
7.8 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
2.45-29.40 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
13.52 +/- 7.37 umol/mmol creatinine |
Infant (0-1 year old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
4.62 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and not Quantified |
|
Not Applicable |
Adult (>18 years old) |
Both |
Normal |
Urine compound detected by GC-MS
|
| Urine |
Detected and Quantified |
|
5.6 (9.3-2.1) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
by LC-MS/MS (Biocrates kit)
|
| Urine |
Detected and Quantified |
|
6.3 (3.4-11.1) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
urine by NMR
|
| Urine |
Detected and Quantified |
|
3.9 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
5.263 (1.316-9.211) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
83.3 +/- 26.0 uM |
Adult (>18 years old) |
Male |
Schizophrenia |
Not Available |
| Blood |
Detected and Quantified |
|
80.2 +/- 22.0 uM |
Adult (>18 years old) |
Female |
Schizophrenia |
Not Available |
| Blood |
Detected and Quantified |
|
31.6 (29.6-33.6) uM |
Adult (>18 years old) |
Both |
Epilepsy |
Acute seizures
|
| Blood |
Detected and Quantified |
|
37.2 (34.3-40.1) uM |
Adult (>18 years old) |
Both |
Epilepsy |
Juvenile myoclonic epilepsy (JME)
|
| Blood |
Detected and Quantified |
|
53.3 (50.3-56.3) uM |
Adult (>18 years old) |
Both |
Epilepsy |
Refractory localization-related epilepsy (RLE)
|
| Blood |
Detected and Quantified |
|
33.06 +/- 8.99 uM |
Adult (>18 years old) |
Both |
Alzheimer's disease |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.035 +/- 0.649 uM |
Adult (>18 years old) |
Not Specified |
celiac disease |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.0018 +/- 0.0003 uM |
Adult (>18 years old) |
Both |
Hypothyroidism |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.6 +/- 0.3 uM |
Adult (>18 years old) |
Both |
Hypothyroidism |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.0 +/- 0.2 uM |
Children (1-13 year old) |
Both |
Hartnup Disease |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.7 +/- 0.27 uM |
Adult (>18 years old) |
Both |
Epilepsy |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.6+/- 0.57 uM |
Adult (>18 years old) |
Both |
Epilepsy |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.7 +/- 0.4 uM |
Adult (>18 years old) |
Not Specified |
Epilepsy |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.68 +/- 0.52 uM |
Adult (>18 years old) |
Both |
Epilepsy |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
14.3 +/- 12.5 uM |
Adult (>18 years old) |
Not Specified |
Epilepsy |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
11.5 +/- 8.2 uM |
Adult (>18 years old) |
Not Specified |
Epilepsy |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
13.0 +/- 5.2 uM |
Children (1-13 year old) |
Not Specified |
Leukemia |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
12.8 +/- 3.5 uM |
Children (1-13 year old) |
Not Specified |
Leukemia |
Acute Lymphoblastic Leukemia (ALL) with Central...
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.42 +/- 0.14 uM |
Adult (>18 years old) |
Not Specified |
Olivopontocerebellar atrophy (OPCA) |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.80 +/- 0.2 uM |
Adult (>18 years old) |
Not Specified |
Spastic Ataxia |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.8 +/- 0.3 uM |
Adult (>18 years old) |
Not Specified |
Hypothyroidism |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.3 +/- 0.32 uM |
Adult (>18 years old) |
Both |
Alzheimer's disease |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.4 +/- 0.13 uM |
Not Specified |
Not Specified |
Friedreich's ataxia |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.67 +/- 0.6 uM |
Adult (>18 years old) |
Both |
Schizophrenia |
Not Available |
| Urine |
Detected and Quantified |
|
7.83 +/- 7.48 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Cachexia |
Not Available |
| Urine |
Detected and Quantified |
|
1.19 +/- 0.23 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Alzheimer's disease |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Cachexia |
- Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I: HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2008 Oct 25.
Pubmed: 18953024
|
| Epilepsy |
- Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.
Pubmed: 14992292
- Botez MI, Young SN: Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain. 1991 Feb;114 ( Pt 1A):333-48.
Pubmed: 1705463
|
| Hartnup disease |
- Jonas AJ, Butler IJ: Circumvention of defective neutral amino acid transport in Hartnup disease using tryptophan ethyl ester. J Clin Invest. 1989 Jul;84(1):200-4.
Pubmed: 2472426
|
| Leukemia |
- Peng CT, Wu KH, Lan SJ, Tsai JJ, Tsai FJ, Tsai CH: Amino acid concentrations in cerebrospinal fluid in children with acute lymphoblastic leukemia undergoing chemotherapy. Eur J Cancer. 2005 May;41(8):1158-63. Epub 2005 Apr 14.
Pubmed: 15911239
|
| Olivopontocerebral atrophy |
- Botez MI, Young SN: Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can J Neurol Sci. 2001 May;28(2):134-40.
Pubmed: 11383938
|
| Hereditary spastic paraplegia |
- Botez MI, Young SN: Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can J Neurol Sci. 2001 May;28(2):134-40.
Pubmed: 11383938
|
| Hypothyroidism |
- Sjoberg S, Eriksson M, Nordin C: L-thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients: a pilot study. Eur J Endocrinol. 1998 Nov;139(5):493-7.
Pubmed: 9849813
|
| Friedreich's ataxia |
- Botez MI, Young SN: Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can J Neurol Sci. 2001 May;28(2):134-40.
Pubmed: 11383938
|
| Schizophrenia |
- Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 1989;99(3):322-7.
Pubmed: 2480613
- Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.
Pubmed: 7595563
|
| Alzheimer's disease |
- Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG: Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids. 2007 Feb;32(2):213-24. Epub 2006 Oct 10.
Pubmed: 17031479
|
|
| Associated OMIM IDs |
|
| External Links |
| DrugBank ID |
DB00150  |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB002250 |
| KNApSAcK ID |
C00001396  |
| Chemspider ID |
6066  |
| KEGG Compound ID |
C00078  |
| BioCyc ID |
TRP  |
| BiGG ID |
33772  |
| Wikipedia Link |
Kalma  |
| NuGOwiki Link |
HMDB00929  |
| Metagene Link |
HMDB00929  |
| METLIN ID |
5879  |
| PubChem Compound |
6305  |
| PDB ID |
TRP  |
| ChEBI ID |
16828  |
| References |
| Synthesis Reference |
Amir-Heidari, Bagher; Thirlway, Jenny; Micklefield, Jason. Stereochemical course of tryptophan dehydrogenation during biosynthesis of the calcium-dependent lipopeptide antibiotics. Organic Letters (2007), 9(8), 1513-1516. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Jonas AJ, Butler IJ: Circumvention of defective neutral amino acid transport in Hartnup disease using tryptophan ethyl ester. J Clin Invest. 1989 Jul;84(1):200-4.
Pubmed: 2472426
- Peng CT, Wu KH, Lan SJ, Tsai JJ, Tsai FJ, Tsai CH: Amino acid concentrations in cerebrospinal fluid in children with acute lymphoblastic leukemia undergoing chemotherapy. Eur J Cancer. 2005 May;41(8):1158-63. Epub 2005 Apr 14.
Pubmed: 15911239
- Cynober LA: Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition. 2002 Sep;18(9):761-6.
Pubmed: 12297216
- Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.
Pubmed: 14992292
- Guchhait RB, Janson C, Price WH: Validity of plasma factor in schizophrenia as measured by tryptophan uptake. Biol Psychiatry. 1975 Jun;10(3):303-14.
Pubmed: 49200
- Sjoberg S, Eriksson M, Nordin C: L-thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients: a pilot study. Eur J Endocrinol. 1998 Nov;139(5):493-7.
Pubmed: 9849813
- Koskiniemi M, Laakso J, Kuurne T, Laipio M, Harkonen M: Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L-tryptophan administration. Acta Neurol Scand. 1985 Feb;71(2):127-32.
Pubmed: 2580417
- Kennedy JS, Gwirtsman HE, Schmidt DE, Johnson BW, Fielstein E, Salomon RM, Shiavi RG, Ebert MH, Parris WC, Loosen PT: Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. Life Sci. 2002 Aug 23;71(14):1703-15.
Pubmed: 12137916
- Bender KI, Lutsevich NF, Lutsevich AN, Kupchikov VV: [Endogenous metabolites as modulators of the transport of drugs by serum albumin] Farmakol Toksikol. 1990 May-Jun;53(3):72-80.
Pubmed: 2201566
- Eklundh T, Eriksson M, Sjoberg S, Nordin C: Monoamine precursors, transmitters and metabolites in cerebrospinal fluid: a prospective study in healthy male subjects. J Psychiatr Res. 1996 May-Jun;30(3):201-8.
Pubmed: 8884658
- Heiman-Patterson TD, Bird SJ, Parry GJ, Varga J, Shy ME, Culligan NW, Edelsohn L, Tatarian GT, Heyes MP, Garcia CA, et al.: Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann Neurol. 1990 Oct;28(4):522-8.
Pubmed: 2174666
- Talbert AM, Tranter GE, Holmes E, Francis PL: Determination of drug-plasma protein binding kinetics and equilibria by chromatographic profiling: exemplification of the method using L-tryptophan and albumin. Anal Chem. 2002 Jan 15;74(2):446-52.
Pubmed: 11811421
- Dunner DL, Heiber S, Perel JM: The effect of L-tryptophan administration on the concentration of probenecid in plasma and cerebrospinal fluid in patients. Psychopharmacology (Berl). 1977 Aug 16;53(3):305-8.
Pubmed: 408860
- Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al.: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992 Oct;115 ( Pt 5):1249-73.
Pubmed: 1422788
- George CF, Millar TW, Hanly PJ, Kryger MH: The effect of L-tryptophan on daytime sleep latency in normals: correlation with blood levels. Sleep. 1989 Aug;12(4):345-53.
Pubmed: 2669092
- Buczko W, Cylwik D, Stokowska W: [Metabolism of tryptophan via the kynurenine pathway in saliva] Postepy Hig Med Dosw (Online). 2005;59:283-9.
Pubmed: 15995595
- Gutsche B, Grun C, Scheutzow D, Herderich M: Tryptophan glycoconjugates in food and human urine. Biochem J. 1999 Oct 1;343 Pt 1:11-9.
Pubmed: 10493906
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4.
Pubmed: 19212411
|